Vontobel Holding’s BridgeBio Pharma BBIO Stock Holding History

Vontobel Holding’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.33M	Sell	17,872 -1,190	-6%	-$86.3K	﹤0.01%	592
2025 Q4	$1.46M	Buy	19,062 +8,620	+83%	+$566K	﹤0.01%	654
2025 Q3	$542K	Buy	10,442 +612	+6%	+$29.8K	﹤0.01%	920
2025 Q2	$424K	Buy	+9,830	New	+$358K	﹤0.01%	948
2024 Q2	–	Sell	-30,216	Closed	-$934K	–	1080
2024 Q1	$934K	Sell	30,216 -595	-2%	-$20.2K	0.01%	605
2023 Q4	$1.24M	Sell	30,811 -35,546	-54%	-$1.07M	0.01%	540
2023 Q3	$1.75M	Sell	66,357 -1,202	-2%	-$34.1K	0.02%	455
2023 Q2	$1.16M	Sell	67,559 -25,161	-27%	-$379K	0.01%	561
2023 Q1	$1.54M	Sell	92,720 -12,858	-12%	-$150K	0.01%	481
2022 Q4	$805K	Buy	+105,578	New	+$1.01M	0.01%	630

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vontobel Holding's BBIO Position: Q1 2026 in Review

Vontobel Holding reduced its BridgeBio Pharma (BBIO) stake by 6.2% in Q1 2026, selling an estimated $86.3K and leaving 17,872 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #592.

Vontobel Holding first reported a position in BBIO in Q4 2022 and has held it in 10 quarters since. The position peaked at $1.75M in Q3 2023. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Vontobel Holding held 17,872 shares of BridgeBio Pharma worth $1.33M as of Q1 2026.
Vontobel Holding sold 1,190 BridgeBio Pharma shares in Q1 2026, an estimated $86.3K.
BridgeBio Pharma made up ﹤0.01% of Vontobel Holding's portfolio in Q1 2026, its #592 holding.
Vontobel Holding first reported a position in BridgeBio Pharma in Q4 2022 and has held it in 10 quarters since.
Vontobel Holding's BridgeBio Pharma position peaked at $1.75M in Q3 2023.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Vontobel Holding's 13F filing for Q1 2026, filed 8 May 2026.